For instance, empagliflozin has been reported to activate adenosine monophosphate-activated protein kinase (AMPK) in the liver ameliorating lipid accumulation in obesity-related nonalcoholic fatty liver disease [54] and in skeletal muscle promoting fat utilization and hence presumably contributing to improved insulin sensitivity [55, 56]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.